Literature DB >> 28605819

Efficacy, Safety, and Duration of a Frameless Fiducial-Less Brain Biopsy versus Frame-based Stereotactic Biopsy: A Prospective Randomized Study.

Miltiadis Georgiopoulos1, John Ellul2, Elisabeth Chroni2, Constantine Constantoyannis1.   

Abstract

BACKGROUND/
OBJECTIVE: We compared the efficacy, duration, safety, length of hospital stay of a frameless fiducial-less brain biopsy with those of the standard frame-based stereotactic biopsy. PATIENTS AND METHODS: This prospective cohort study enrolled 56 adult patients: (1) for whom no conclusive diagnosis could be reached noninvasively; (2a) who had lesions involving deep-seated and eloquent areas, multifocal lesions, or lesions for which craniotomy and lesion removal was not indicated, or (2b) were poor candidates for craniotomy (> 80 years of age and/or with serious comorbidities). Frameless and frame-based biopsy were performed in 28 patients each
RESULTS: A diagnosis was not made in four cases (14.3%) of the frame-based biopsy group and in three cases (10.7%) of the frameless biopsy group, in spite of accurate targeting (p = 1.0). The mean duration of the whole procedure (preparatory steps outside the operating room [OR], inside the OR, surgery) was 111.3 minutes for the frame-based biopsy and 79.1 minutes for the frameless biopsy (p = 0.001). No statistically significant differences between the two methods were found concerning new neurologic symptoms, new abnormal findings in postoperative computed tomography (CT) and length of postoperative hospital stay (LOS). The smallest diameter of a successfully biopsied lesion was 15 mm for both groups.
CONCLUSIONS: The frameless fiducial-less brain biopsy was equally efficacious and safe compared with the standard stereotactic frame-based biopsy. The overall duration of frameless biopsy is shorter than that of frame-based biopsy, mainly because the preparatory steps in frameless biopsy require less time. However, the overall time spent in the OR did not differ between the two groups. The LOS also did not differ significantly. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2017        PMID: 28605819     DOI: 10.1055/s-0037-1602697

Source DB:  PubMed          Journal:  J Neurol Surg A Cent Eur Neurosurg        ISSN: 2193-6315            Impact factor:   1.268


  6 in total

1.  Indicators of correct targeting in stereotactic biopsy of intracranial lesions.

Authors:  Osvaldo Vilela-Filho; Jairo Porfírio; Lissa C Goulart
Journal:  Surg Neurol Int       Date:  2022-06-17

2.  The diagnostic quality of needle brain biopsy specimens obtained with different sampling methods - Experimental study.

Authors:  Piotr Trojanowski; Bożena Jarosz; Dariusz Szczepanek
Journal:  Sci Rep       Date:  2019-05-30       Impact factor: 4.379

3.  Frame-based versus frameless stereotactic brain biopsies: A systematic review and meta-analysis.

Authors:  Mohamad Ali Kesserwan; Husain Shakil; Melissa Lannon; Ryan McGinn; Laura Banfield; Siddharth Nath; Mazen Alotaibi; Ekkehard Kasper; Sunjay Sharma
Journal:  Surg Neurol Int       Date:  2021-02-10

4.  Robot-assisted stereotactic brain biopsy: systematic review and bibliometric analysis.

Authors:  Hani J Marcus; Vejay N Vakharia; Sebastien Ourselin; John Duncan; Martin Tisdall; Kristian Aquilina
Journal:  Childs Nerv Syst       Date:  2018-05-10       Impact factor: 1.475

5.  Frame-based stereotactic biopsies using an intraoperative MR-scanner are as safe and effective as conventional stereotactic procedures.

Authors:  Jan-Oliver Neumann; Benito Campos; Bilal Younes; Martin Jakobs; Christine Jungk; Christopher Beynon; Andreas von Deimling; Andreas Unterberg; Karl Kiening
Journal:  PLoS One       Date:  2018-10-23       Impact factor: 3.240

6.  High Precision Bone Cutting by Er: YAG Lasers Might Minimize the Invasiveness of Navigated Brain Biopsies.

Authors:  Thanh Tu Ha; Florian M Thieringer; Martin Bammerlin; Dominik Cordier
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.